[Comment] COVID-19 vaccines in patients with cancer

Navigating uncertainties generated by structural barriers to scientific evidence is often challenging. For instance, the systematic exclusion of patients with cancer from the pivotal clinical trials of COVID-19 vaccines is arguably almost inexcusable.1 Patients with cancer have been included in the priority category for vulnerability to COVID-19 since the early phases of the pandemic.2 There is, therefore, an urgent need to better understand the efficacy and safety of COVID-19 vaccines in immunosuppressed individuals, as recurrent exclusion of these and other vulnerable groups from ongoing studies of COVID-19 vaccines will result in imprecise predictive health models, which will in turn have consequences on successive waves of the pandemic.

Lascia un commento